Trends in number of COVID-19 cases in the United States

January 23, 2020 – January 30, 2022

74,282,892 total cases
7-day Moving Average Cases: 497,296

Trends in the number of COVID-19 deaths in the United States

January 23, 2020 – January 30, 2022

Total Deaths: 881,887
7-day Moving Avg. Deaths: 2,234

Rates of COVID-19 deaths by vaccination status

April 04 – December 25, 2021 (28 U.S. Jurisdictions)

In November, unvaccinated adults aged 18 years and older had:

15X
Risk of Dying from COVID-19

compared to fully vaccinated adults

Percent of COVID-19 vaccination coverage by age and date administered, United States

December 14, 2020 – February 01, 2022

<table>
<thead>
<tr>
<th>Age Group</th>
<th>Percent Receiving ≥1 dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>75+ years</td>
<td>95.0%</td>
</tr>
<tr>
<td>65-74 years</td>
<td>95.0%</td>
</tr>
<tr>
<td>50-64 years</td>
<td>91.4%</td>
</tr>
<tr>
<td>40-49 years</td>
<td>84.7%</td>
</tr>
<tr>
<td>25-39 years</td>
<td>77.5%</td>
</tr>
<tr>
<td>18-24 years</td>
<td>75.0%</td>
</tr>
</tbody>
</table>

COVID-19-associated hospitalizations and deaths prevented by COVID-19 vaccination in the United States

- COVID-19 associated hospitalizations prevented\(^1\,^2\):
  - Estimated up to 10.3 million hospitalizations averted through November 2021

- COVID-19 associated deaths prevented\(^1\,^3\):
  - Estimated up to 1.1 million deaths averted through November 2021

FDA updates

Moderna COVID-19 vaccine (Spikevax) received FDA approval

- On January 31, 2022: FDA approved the Moderna COVID-19 vaccine (Spikevax) for individuals 18 years of age and older
  - Spikevax biologics license application (BLA) builds upon the data and information that supported the EUA, such as preclinical and clinical data, as well as details of the manufacturing process and sites where the vaccine is made
  - Spikevax has the same formulation as the EUA Moderna COVID-19 vaccine and can be used interchangeably with the EUA Moderna COVID-19 vaccine to provide the COVID-19 vaccination primary series
  - Moderna COVID-19 vaccine remains under EUA for the following indications:
    - Third primary series doses for individuals 18 years of age and older who have been determined to have certain kinds of immunocompromise
    - Single booster dose for individuals 18 year of age and older at least five months after completing a primary series

COVID-19 vaccine Work Group activities
January/February 2022

Reviewed data:

- Safety and efficacy of Moderna COVID-19 vaccine from the Phase III clinical trial
- Meta-analysis for global real-world effectiveness data for Moderna COVID-19 vaccine
- Safety updates for Moderna COVID-19 vaccine/mRNA COVID-19 vaccines
- GRADE and Evidence to Recommendation (EtR) Framework for Moderna COVID-19 vaccine primary series
- Global data for myocarditis after mRNA COVID-19 vaccines
- Emerging data about safety/effectiveness of longer inter-dose intervals for mRNA COVID-19 vaccines
Agenda: Friday February 4, 2022

- mRNA 1273 COVID-19 vaccine BLA safety and efficacy data
  Dr. Rituparna Das (Moderna)

Break

PUBLIC COMMENT

- Updates on myocarditis and pericarditis following Moderna COVID-19 vaccination
  Dr. Shimabukuro (CDC)

- Updates on myocarditis outcomes: MOVING
  Dr. Kracalic (CDC)

- VaST assessment
  Dr. Talbot (VaST Chair)

Break

GRADE: Moderna COVID-19 vaccine
Dr. Wallace (CDC)

EtR Framework: Moderna COVID-19 vaccine primary series in adults ≥18 years of age
Dr. Oliver (CDC)

Discussion

VOTE

Moderna COVID-19 vaccine for individuals ≥18 years of age
Updates to Clinical Considerations

Canadian experience and evidence with COVID-19 vaccine primary series extended intervals

VSD: Myocarditis after Moderna and Pfizer/BioNTech COVID-19 vaccines

Myocarditis and COVID-19 vaccine intervals: International data and policies

Summary and Work Group Interpretation:
Extended intervals for mRNA COVID-19 vaccines

Discussion
Work Group members

ACIP members
- Matthew Daley (chair)
- Beth Bell
- Grace Lee
- Keipp Talbot
- Oliver Brooks

Ex-officio/government members
- FDA: Doran Fink, Rachel Zhang
- NIH: Chris Roberts
- IHS: Thomas Weiser, Uzo Chukwuma
- DOD: Bryan Schumacher
- CMS: Jeff Kelman
- BARDA: Christine Oshansky
- HHS: David Kim

CDC Lead
- Sara Oliver

Liaisons
- AAFP: Jonathan Temte
- AAP: Sean O’Leary
- ACOG: Denise Jamieson (primary), Laura Riley (alternate)
- ACP: Jason Goldman
- AGS: Ken Schmader
- AIM: Rob Shechter (primary), Jane Zucker (alternate)
- AMA: Sandra Fryhofer
- ANA: Kendra McMillan (primary), Ruth Francis (alternate)
- APhA: Michael Hogue
- ASTHO: Marcus Plescia
- CSTE: Susan Lett (primary), Christine Hahn (alternate)
- IDSA: Jeff Duchin (primary), Carol Baker (alternate)

Liaisons, cont’d
- NACCHO: Matt Zahn (primary), Jeff Duchin (alternate)
- NACI: Matthew Tunis
- NFID: Bill Schaffner (primary), Marla Dalton (alternate)
- NMA: Patricia Whitley-Williams
- SHEA: Marci Drees

Consultants
- Ed Belongia
- Kathy Kinlaw
- Dayna Matthew
- Kathleen Neuzil
- Stanley Perlman
- Peter Szilagyi
- Jose Romero
- Hank Bernstein
CDC participants

- Sarah Mbaeyi
- Evelyn Twentyman
- Tara Jatloui
- Anthony Fiore
- Mary Chamberland
- Amanda Cohn
- Jack Gersten
- Monica Godfrey
- Stephen Hadler
- Danielle Moulia
- Megan Wallace
- Susan Goldstein
- Jefferson Jones
- Edwin Shanley
- Rita Helfand
- Cynthia Jorgensen
- Megan Lindley
- Ruth Link-Gelles
- Jessica MacNeil
- Lauri Markowitz
- Valerie Morelli
- Meredith McMorrow
- Rebecca Morgan
- Titilope Oduyebo
- Heather Scobie
- Edwin Shanley
- Tom Shimabukuro
- Natalie Thornburg
- Thomas Clark
- Doug Campos-Outcalt
- Jillian Doss-Walker
- Andrew Kroger
- Jean Cox-Ganser
- Melinda Wharton
- Kate Woodworth
- JoEllen Wolicki
- Yon Yu
- Kristin Nordland
- Kevin Chatham-Stevens
- Erin Tromble
- Dana Meaney-Delman
- Thomas Clark
- Sam Graitcer
- Lisa Grohskopf
Thank you!

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.